Clinical relevance of CD10, BCL-6 and multiple myeloma-1 expression in diffuse large B-cell lymphomas in Malaysia

• Published in: Pathology international 2008-09, Vol.58 (9), p.572-579
• Main Authors: Peh, Suat-Cheng, Gan, Gin-Gin, Lee, Lin-Kiat, Eow, Geok-Im
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; BCL-2; BCL-6; Biomarkers, Tumor - metabolism; CD10; Child; diffuse large B-cell lymphoma; Disease-Free Survival; DNA-Binding Proteins - metabolism; EBV; Female; Humans; Immunoenzyme Techniques; Interferon Regulatory Factors - metabolism; Lymphoma, Large B-Cell, Diffuse - metabolism; Lymphoma, Large B-Cell, Diffuse - mortality; Lymphoma, Large B-Cell, Diffuse - pathology; Malaysia - epidemiology; Male; Middle Aged; MUM-1; Neprilysin - metabolism; Proto-Oncogene Proteins c-bcl-6; Survival Rate
• ISSN: 1320-5463; 1440-1827
• DOI: 10.1111/j.1440-1827.2008.02273.x

Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma, and it is recognized to constitute a heterogenous group of neoplasms. It can be divided into germinal center B‐cell‐like (GCB) and non‐GCB subgroups. The aim of the present study was to evaluate the utility of immunophenotype subgrouping of DLBCL in a cohort of multi‐ethnic Asian patients. A total of 84 reconfirmed de novo DLBCL were immunostained for the expression of CD10, BCL‐2, BCL‐6 and multiple myeloma‐1. Thirty‐three (39.3%) had the GCB phenotype, and the remainder (60.7%), the non‐GCB phenotype. The results concur with most reports using a similar method of stratification. Forty‐five patients had complete demographic and phenotype studies and 42 patients did not have rituximab treatment and had sufficient data for survival rate analysis. Similar to other studies, patients with combined low and low–intermediate International Prognostic Index score had better overall survival (P = 0.006). But patients with GCB phenotype did not have better prognosis, and BCL‐2 expression was not associated with better prognosis. The expression of BCL‐6 was associated with lower overall survival rate (P = 0.038). No apparent difference in overall and disease‐free survival was noted between patients with GCB and non‐GCB disease. BCL‐6 expression by tumor cells appears to be associated with poorer prognosis.